Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
88 hedge funds and large institutions have $1.31B invested in Verona Pharma in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 10 closing their positions.
374% more call options, than puts
Call options by funds: $29.8M | Put options by funds: $6.29M
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
177% more capital invested
Capital invested by funds: $474M → $1.31B (+$838M)
129% more funds holding in top 10
Funds holding in top 10: 7 → 16 (+9)
29% more funds holding
Funds holding: 68 → 88 (+20)
0.33% more ownership
Funds ownership: 8.93% → 9.26% (+0.33%)
4% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.4M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$15.2M |
| 3 |
Jennison Associates
New York
|
+$13.7M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$9.54M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.26M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.83M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.66M |
VRNA Hedge Fund Activity: Q4 2022 in Review
88 of the 6,206 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2022, worth a combined $1.31B — up 177% from $474M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new VRNA positions and 10 closed out — a net gain of 22 holders — while 24 added to existing stakes and 25 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.4M. The largest seller was OrbiMed, cutting an estimated $14.9M.
- 88 institutional investors held Verona Pharma (VRNA) as of Q4 2022, up from 68 in Q3 2022.
- Funds reported $1.31B of Verona Pharma stock for Q4 2022, up 177% quarter-over-quarter.
- 32 funds opened new Verona Pharma positions in Q4 2022 and 10 closed out, a net change of +22 holders.
- The largest Verona Pharma buyer in Q4 2022 was Fidelity Investments, an estimated $23.4M added.
- The largest Verona Pharma seller in Q4 2022 was OrbiMed, an estimated $14.9M sold.
Based on aggregated 13F filings for Q4 2022.